What’s New In Ulcerative Colitis?

DDW 2022 Conference Coverage
M

Efficacy and Safety of Mirikizumab as Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Results From The Phase 3 LUCENT-2 Study

By DDW 2022 Conference Coverage FEATURING Marla Dubinsky
By DDW 2022 Conference Coverage FEATURING Marla Dubinsky
431 views
June 29, 2022
Mirikizumab was approved by the FDA on October 26, 2023
Comments 0
Login to view comments. Click here to Login
17:18

Medical Therapy in IBD: Past, Present, and Future

David Choi

672 views
11:28

Bowel Urgency: Important but Neglected in Ulcerative Colitis

Subrata Ghosh

334 views
14:53

IL12/23 and IL23 Selective Inhibition in Inflammatory Bowel Disease

Gil Melmed

609 views
09:17

Mirikizumab Achieved Comprehensive Disease Control in Patients with …

Stefan Schreiber

615 views
28:07

Guidelines for Ulcerative Colitis Diagnosis and Management

UChicago Medicine

D. T. Rubin

3.4K views
21:33

Surgery for Ulcerative Colitis: Current Techniques

Columbia University

A. D'Hoore

301 views